ClinicaliQ Trial Snapshot
- Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma — Recruiting • Oncology • NCT04234022.
- One-sentence summary:.
- Researchers are testing whether Imuthiol, a cheap drug toxic to cancer stem cells, could be effective alone or combined with existing myeloma drugs.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordable drug to study on it's own as well as in combination with other drugs in myeloma…